Concord Drugs Limited

BSE: 538965
Concord Drugs Limited - pharma in Telangana, India. FY 2026 financials & compliance.
CIN L24230TG1995PLC020093 Incorporated 24 April 1995 ROC Hyderabad HQ Telangana, India
Active Listed - BSE: 538965 Public Limited Company pharma MSME · Medium
Data last updated
Market Cap
₹86.94 Cr
CONCORD · BSE
Share Price
₹63.35
-4.00% today
Revenue
₹78.77 Cr
FY 2025-26 · +74.1% YoY
EBITDA
₹4.55 Cr
Margin 5.8%
Net Profit
₹1.05 Cr
FY 2025-26 · +218.2% YoY
P/E (TTM)
41.1x
P/B 1.8x
Authorised capital
₹15.5 Cr
Registered with MCA
Paid-up capital
₹13.18 Cr
Issued & subscribed

About Concord Drugs Limited

Data last updated:

Concord Drugs Limited is a public limited company based in Telangana, India. It operates in the API manufacturers segment of the pharmaceuticals sector. It was incorporated on 24 April 1995 and has been in existence for over 31 years.

The company is registered with the Registrar of Companies (ROC), Hyderabad, under CIN L24230TG1995PLC020093. Its GSTIN is 36AAACC8171D1ZV (Telangana). The company holds 3 GST registrations, of which 1 is active. It is a listed company as per MCA records. Its shares are listed on BSE: 538965.

The company has an authorised share capital of ₹15.5 Cr and a paid-up capital of ₹13.18 Cr. It is led by directors including Nagi Reddy Seelam (Managing Director) and Koni Reddy Seelam (Whole-Time Director).

Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Survey No.249 Brahmanapally Village Hayatnagar Mandal R.R.D Ist – 501511, Telangana, India.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹78.77 Cr, a growth of 74.1% compared to the previous year. For the same year it recorded a net profit of ₹1.05 Cr (net margin 1.3%) and EBITDA of ₹4.55 Cr (EBITDA margin 5.8%). The net worth stands at ₹48.52 Cr (up 42.2% YoY). Total assets are valued at ₹65.9 Cr (up 17.1% YoY).

The company has about 20 employees on its provident fund (EPFO) records. Its group structure includes 1 subsidiary.

The company is associated with 1 brand: Concord Drugs. As per MCA filings, the company has open charges of ₹19.33 Cr and satisfied charges of ₹7.4 Cr on record. Court records list 57 cases involving the company, including 12 filed by the company and 45 filed against it; 11 cases are pending. The company has 30 deals on record (29 market trades, 1 funding round), with disclosed funding of ₹4.15 Cr; the latest was in July 2025. Its 9 peer companies in the Pharma industry (API Manufacturers), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 5 larger and 4 smaller; the largest is Abhilasha Pharma Private Limited with revenue of ₹46.09 Cr.

Concord Drugs Limited is registered as a medium enterprise under the Udyam registration framework (Reg. No. UDYAM-TS-09-0025745). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website concorddrugs.in.

Company details

CIN L24230TG1995PLC020093
Registration Number 020093
Incorporation Date 24 April 1995
ROC Hyderabad
Listing Status Listed - Listed on BSE (538965)
Company Status Active
Date of Last AGM 30 September 2025
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant
MSME Classification Medium
Udyam Registration UDYAM-TS-09-0025745

CIN history

Concord Drugs has one previous CIN (Corporate Identification Number): L24230AP1995PLC020093. The current CIN is L24230TG1995PLC020093, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L24230TG1995PLC020093Current
L24230AP1995PLC020093Previous
Key People
Nagi Reddy Seelam Managing Director Koni Reddy Seelam Whole-Time Director Seelam Manojkumarreddy Whole-Time Director

Recognitions & Rankings of Concord Drugs

MSME (Udyam registered) Ministry of MSME
Category
Medium (2023-24)
Udyam number
UDYAM-TS-09-0025745

Contact details

Concord Drugs Limited's registered office is in Telangana. Its website is concorddrugs.in. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Website
    concorddrugs.in
  • Social Media
  • Registered Address
    Survey No.249 Brahmanapally Village Hayatnagar Mandal R.R.D Ist – 501511, Telangana, India
  • Industry
    Pharma, API Manufacturers

To see the full contact details of Concord Drugs Limited, buy the company report.

Comprehensive company report
Concord Drugs Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Concord Drugs operates one associated brand: Concord Drugs. Each brand links to its own profile.

BrandDescriptionWebsite
Concord Drugs
Manufacturer of pharmaceutical formulations and ready-to-fill pelletsconcorddrugs.in

Business activity

The main business activity of Concord Drugs is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
CManufacturingC6Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products

To see the full business activity and turnover split of Concord Drugs Limited, buy the company report.

Financials of Concord Drugs Limited

FY 2025-26 filings available

Concord Drugs Limited reported revenue of ₹78.77 Cr (up 74.1% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹78.77 Cr
+74.1% YoY
EBITDA
₹4.55 Cr
+10.2% YoY
Profit After Tax
₹1.05 Cr
+218.2% YoY
Net Worth
₹48.52 Cr
+42.2% YoY
Total Assets
₹65.90 Cr
+17.1% YoY
Total Debt
₹14.51 Cr
-24.6% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22
Income statement
Revenue78.7745.2444.9252.0858.96
Revenue growth+74.1%+0.7%-13.8%-11.7%-
EBITDA4.554.134.024.585.58
EBITDA margin+5.8%+9.1%+9.0%+8.8%+9.5%
Profit before tax1.470.680.601.252.24
Net profit1.050.330.440.991.59
Net profit margin+1.3%+0.7%+1.0%+1.9%+2.7%
EPS (₹)0.950.340.471.061.82
Balance sheet
Total assets65.9056.2654.2051.1346.88
Net worth48.5234.1133.8231.7028.36
Total debt14.5119.2417.5216.9616.43
Cash & bank0.750.230.180.100.07
Net working capital44.9632.5033.3936.8932.99
Cash flow
Cash from operations(5.75)3.720.791.660.77
Cash from investing(1.13)(2.32)(1.01)(2.27)(2.44)
Cash from financing7.04(1.43)0.280.621.68
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue20.9537.9016.9910.2813.6110.3910.8012.37
Revenue growth (YoY)+53.9%+264.8%+57.3%-16.9%+16.4%---
Other income0.000.000.000.000.000.000.000.00
EBITDA2.291.500.941.101.021.041.390.88
EBITDA margin+10.9%+4.0%+5.5%+10.7%+7.5%+10.0%+12.9%+7.1%
Depreciation0.350.350.310.340.370.380.370.34
Interest0.400.400.340.490.490.610.500.47
Profit before tax1.540.750.290.270.160.050.520.07
Tax0.430.220.080.080.040.020.310.03
Net profit1.110.530.210.190.120.030.210.04
EPS (₹)0.850.470.160.190.120.040.230.04
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue75.8836.9343.2651.3158.9651.3651.34
Revenue growth+105.5%-14.6%-15.7%-13.0%+14.8%+0.0%-
EBITDA4.263.773.674.335.583.223.33
EBITDA margin+5.6%+10.2%+8.5%+8.4%+9.5%+6.3%+6.5%
Profit before tax1.440.640.551.122.244.290.45
Net profit1.030.290.410.881.590.400.32
Net profit margin+1.4%+0.8%+1.0%+1.7%+2.7%+0.8%+0.6%
EPS (₹)0.930.300.420.961.823.750.38
Balance sheet
Total assets63.9153.9251.6249.8046.8842.1935.59
Net worth48.5234.1133.8231.7028.3626.7623.48
Total debt12.5216.9114.9315.6316.4312.979.57
Cash & bank0.740.220.170.100.070.060.04
Net working capital42.1729.4030.0935.1032.9929.0223.29
Cash flow
Cash from operations(6.22)2.041.962.240.771.622.48
Cash from investing(1.13)(2.32)(1.21)(2.27)(2.44)(3.67)(0.84)
Cash from financing7.510.26(0.69)0.051.682.07(1.79)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue20.9035.5616.8410.0713.387.9610.7711.84
Revenue growth (YoY)+56.2%+346.7%+56.4%-15.0%+110.7%---
Other income0.000.000.020.000.000.000.000.01
Total expenses18.6634.1315.979.0712.457.049.4611.05
EBITDA2.241.430.871.000.930.921.310.79
EBITDA margin+10.7%+4.0%+5.2%+9.9%+7.0%+11.6%+12.2%+6.7%
Depreciation0.350.350.300.340.370.370.370.34
Interest0.350.340.300.400.420.530.430.39
Profit before tax1.540.740.290.260.140.020.510.07
Tax0.430.210.080.080.040.010.300.02

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 30 Oct 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue20.9537.9016.9910.2813.6110.3910.8012.37
Revenue growth (YoY)+53.9%+264.8%+57.3%-16.9%+16.4%---
Other income0.000.000.000.000.000.000.000.00
EBITDA2.291.500.941.101.021.041.390.88
EBITDA margin+10.9%+4.0%+5.5%+10.7%+7.5%+10.0%+12.9%+7.1%
Depreciation0.350.350.310.340.370.380.370.34
Interest0.400.400.340.490.490.610.500.47
Profit before tax1.540.750.290.270.160.050.520.07
Tax0.430.220.080.080.040.020.310.03
Net profit1.110.530.210.190.120.030.210.04
EPS (₹)0.850.470.160.190.120.040.230.04
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22
Revenue78.7745.2444.9252.0858.96
Revenue growth+74.1%+0.7%-13.8%-11.7%-
Other income0.000.010.010.010.10
Total expenses74.2241.1140.9047.5053.38
Employee cost0.003.555.003.844.14
EBITDA4.554.134.024.585.58
EBITDA margin+5.8%+9.1%+9.0%+8.8%+9.5%
Depreciation1.371.431.561.631.76
Interest1.712.031.871.711.68
Profit before tax1.470.680.601.252.24
Tax0.420.350.160.260.65
Net profit1.050.330.440.991.59
Net profit margin+1.3%+0.7%+1.0%+1.9%+2.7%
EPS (₹)0.950.340.471.061.82
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22
Equity & liabilities
Share capital13.1810.0010.009.328.74
Reserves & surplus33.5024.1123.8221.8219.62
Shareholders' funds (net worth)48.5234.1133.8231.7028.36
Minority interest0.000.000.000.000.00
Secured loans14.5119.2417.5216.9616.43
Unsecured loans0.000.000.000.000.00
Total debt14.5119.2417.5216.9616.43
Total liabilities65.9056.2654.2051.1346.88
Assets
Gross block40.6539.9237.9637.6137.12
Net block11.5812.2111.6712.9213.97
Capital work in progress2.432.001.630.920.55
Investments0.780.800.840.890.00
Inventories25.5225.2722.9220.0617.49
Sundry debtors24.3813.6012.7315.8122.86
Cash & bank balances0.750.230.180.100.07
Loans & advances2.671.661.697.481.48
Total current assets53.3240.7637.5243.4541.90
Total current liabilities8.368.264.136.568.91
Net working capital44.9632.5033.3936.8932.99
Total assets65.9056.2654.2051.1346.88
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22
Opening cash0.120.150.080.060.04
Net cash from operating activities(5.75)3.720.791.660.77
Net cash from investing activities(1.13)(2.32)(1.01)(2.27)(2.44)
Net cash from financing activities7.04(1.43)0.280.621.68
Net change in cash0.16(0.02)0.070.020.01
Closing cash0.750.230.180.100.07
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22
Growth
Sales growth+74.1%+0.7%-13.8%-11.7%-
EBITDA growth+10.2%+2.7%-12.2%-17.9%-
PBT growth+116.2%+13.3%-52.0%-44.2%+9997.0%
Net income growth+218.2%-25.0%-55.6%-37.7%-
Revenue CAGR (3Y)+14.8%-8.5%---
EBITDA CAGR (3Y)-0.2%-9.5%---
Profitability & leverage
Net income margin+1.3%+0.7%+1.0%+1.9%+2.7%
Return on capital employed-+4.9%+4.8%+6.0%+8.4%
Return on net worth-+1.0%+1.4%+3.3%+5.6%
Debt / equity-0.540.530.560.58
Long-term debt / equity-0.030.040.060.06
Interest cover53.7775.1976.0257.9743.98
Efficiency & per share
Fixed asset turnover-1.161.191.391.59
Inventory turnover-1.882.092.773.37
Debtors turnover-3.443.152.692.58
EPS (₹)0.950.340.471.061.82
Dividend per share (₹)0.000.000.000.000.00
Book value per share (₹)0.0034.1133.8233.4332.44
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue20.9035.5616.8410.0713.387.9610.7711.84
Revenue growth (YoY)+56.2%+346.7%+56.4%-15.0%+110.7%---
Other income0.000.000.020.000.000.000.000.01
Total expenses18.6634.1315.979.0712.457.049.4611.05
EBITDA2.241.430.871.000.930.921.310.79
EBITDA margin+10.7%+4.0%+5.2%+9.9%+7.0%+11.6%+12.2%+6.7%
Depreciation0.350.350.300.340.370.370.370.34
Interest0.350.340.300.400.420.530.430.39
Profit before tax1.540.740.290.260.140.020.510.07
Tax0.430.210.080.080.040.010.300.02
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue75.8836.9343.2651.3158.9651.3651.34
Revenue growth+105.5%-14.6%-15.7%-13.0%+14.8%+0.0%-
Other income0.000.010.010.010.103.860.12
Total expenses71.6233.1639.5946.9853.3848.1448.01
Employee cost0.003.313.873.554.143.473.27
EBITDA4.263.773.674.335.583.223.33
EBITDA margin+5.6%+10.2%+8.5%+8.4%+9.5%+6.3%+6.5%
Depreciation1.361.421.541.601.761.371.46
Interest1.461.721.591.621.681.421.54
Profit before tax1.440.640.551.122.244.290.45
Tax0.410.350.140.240.651.010.13
Net profit1.030.290.410.881.590.400.32
Net profit margin+1.4%+0.8%+1.0%+1.7%+2.7%+0.8%+0.6%
EPS (₹)0.930.300.420.961.823.750.38
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital13.1810.0010.009.328.748.748.74
Reserves & surplus33.5024.1123.8221.8219.6218.0214.74
Shareholders' funds (net worth)48.5234.1133.8231.7028.3626.7623.48
Secured loans12.5216.9114.9315.6316.4312.969.35
Unsecured loans0.000.000.000.000.000.010.22
Total debt12.5216.9114.9315.6316.4312.979.57
Total liabilities63.9153.9251.6249.8046.8842.1935.59
Assets
Gross block40.6239.8937.9237.6137.1235.2230.98
Net block11.5512.1811.6312.8613.9713.8310.52
Capital work in progress2.432.001.630.920.550.001.00
Investments1.621.621.621.420.000.000.00
Inventories18.3519.1318.5017.5017.4911.8716.43
Sundry debtors28.1312.6713.9716.3522.8620.7325.45
Cash & bank balances0.740.220.170.100.070.060.04
Loans & advances2.251.401.657.451.483.373.65
Total current assets49.4733.4234.2941.4041.9036.0345.57
Total current liabilities7.304.024.206.308.917.0122.28
Net working capital42.1729.4030.0935.1032.9929.0223.29
Total assets63.9153.9251.6249.8046.8842.1935.59
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash0.120.140.080.040.040.010.16
Net cash from operating activities(6.22)2.041.962.240.771.622.48
Net cash from investing activities(1.13)(2.32)(1.21)(2.27)(2.44)(3.67)(0.84)
Net cash from financing activities7.510.26(0.69)0.051.682.07(1.79)
Net change in cash0.16(0.02)0.060.030.010.02(0.15)
Closing cash0.740.220.170.100.070.060.04
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+105.5%-14.6%-15.7%-13.0%+14.8%+0.0%-
EBITDA growth+13.0%+2.7%-15.2%-22.4%+73.3%-3.3%-
PBT growth+125.0%+16.4%-50.9%-50.0%-47.8%+853.3%+2.3%
Net income growth+255.2%-29.3%-53.4%-44.7%+297.5%+25.0%-
Revenue CAGR (3Y)+13.9%-14.4%-5.6%-0.0%+7.0%-0.3%-3.7%
EBITDA CAGR (3Y)-0.5%-12.3%+4.5%+9.2%+15.2%-12.5%-15.4%
Profitability & leverage
Net income margin+1.4%+0.8%+1.0%+1.7%+2.7%+6.4%+0.6%
Return on capital employed-+4.5%+4.2%+5.7%+8.8%+5.0%+5.6%
Return on net worth-+0.9%+1.3%+3.0%+5.8%+1.6%+1.4%
Debt / equity-0.470.470.530.530.450.42
Long-term debt / equity-0.020.020.050.100.090.03
Interest cover50.3473.1974.6559.3443.9876.7682.35
Efficiency & per share
Fixed asset turnover-0.951.151.371.631.551.66
Inventory turnover-1.962.402.934.023.632.93
Debtors turnover-2.772.852.622.712.221.39
EPS (₹)0.930.300.420.961.823.750.38
Dividend per share (₹)0.000.000.000.000.000.000.00
Book value per share (₹)0.0034.1133.8233.4332.4430.6126.86

To see the full year-wise statements and ratios of Concord Drugs Limited, buy the company report.

Board of directors of Concord Drugs Limited

Concord Drugs has 6 current directors and 13 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Nagi Reddy Seelam
Also directs: Cortex Laboratories Private Limited
Managing Director04 Apr 200323 Years 6 MonthsCurrent
Koni Reddy Seelam
Also directs: Proton Remedies Private Limited
Whole-Time Director10 Jun 201115 Years 4 MonthsCurrent
Seelam Manojkumarreddy
Also directs: Cortex Laboratories Private Limited, Proton Remedies Private Limited, Seelam Laboratories Private Limited
Whole-Time Director13 Aug 20215 Years 2 MonthsCurrent
Nagavenkatahareeshkumar SolletiDirector13 Feb 20215 Years 8 MonthsCurrent
Sumeela KasuDirector01 Jun 20224 Years 4 MonthsCurrent
Satyam Reddy GopidiDirector30 Sep 20251 Years 1 MonthsCurrent
View all directors

Peer comparison

Concord Drugs Limited is compared with the 9 companies closest to it by revenue in the Pharma industry (API Manufacturers), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
Concord Drugs Limitedthis company₹78.77 Cr (FY 2026)₹1.05 Cr1.3%74.1%20Telangana, India
Abhilasha Pharma Private Limited₹46.09 Cr (FY 2025)-2.0%Ahmedabad, Gujarat, India
R L Chemical Industries Private Limited₹45.99 Cr (FY 2025)-12.0%Mumbai, Maharashtra, India
Maithili Life Sciences Private Limited₹45.89 Cr (FY 2023)20.0%Hyderabad, Telangana, India
Sainor Life Sciences Private Limited₹45.59 Cr (FY 2021)-18.0%Hyderabad, Telangana, India
Amara Labs Private Limited₹45.37 Cr (FY 2021)173.0%Hyderabad, Telangana, India
Raghava Life Sciences Private Limited₹45.14 Cr (FY 2025)-26.0%Hyderabad, Telangana, India
S.V.Chem Intermediates Private Limited₹44.99 Cr (FY 2025)-11.0%Thiruporur, Tamil Nadu, India
FR Chem Private Limited₹44.47 Cr (FY 2025)59.0%Ahmedabad, Gujarat, India
Unidrug Innovative Pharma Technologies Limited₹44.46 Cr (FY 2025)28.0%Indore, Madhya Pradesh, India

To see the full peer comparison of Concord Drugs Limited, buy the company report.

Auditor

Concord Drugs Limited is audited by Pundarikashyam and Associates for the financial year 2024.

Auditor firmFinancial yearFirm registration number
Pundarikashyam and AssociatesFY 2024011330S

Shareholding

Shareholding for the quarter ended Mar 2026: promoters hold 54.40%, foreign institutional investors hold 0.00%, domestic institutional investors hold 0.00% and retail and other public shareholders hold 45.60%.

Promoters: 54.40%Retail & Others: 45.60%
Mar 2026
QUARTER
54.40% Promoters
45.60% Retail & Others
Promoter holding - history
Now 54.40% · Mar 2026High 54.40% · Jun 2025Low 54.40% · Jun 2025
53%53.8%54.5%55.3%56%Jun 2025Sep 2025Dec 2025Mar 2026Jun 2025: 54.40%Sep 2025: 54.40%Dec 2025: 54.40%Mar 2026: 54.40%54.40%54.40%
Shareholding trend - last 6 quarters
Mar 2026Dec 2025Sep 2025Jun 2025
Promoters54.40%54.40%54.40%54.40%
Public45.60%45.60%45.60%45.60%

Charges & borrowings

Open charges
₹19.33 Cr
Satisfied charges
₹7.4 Cr
Breakdown by lending institutions
State Bank of India₹18.93 Cr
Others₹0.40 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
25 Feb 2026101249024Others₹40 LakhOpen
17 Dec 201110394597State Bank of India₹18.93 CrOpen
11 Mar 2022100568210Others₹5 CrSatisfied
10 Nov 200580030887Punjab National Bank₹1.4 CrSatisfied
01 Jan 199890131209Small Industries Development Bank of India₹50 LakhSatisfied

To see the full charge records of Concord Drugs Limited, buy the company report.

Total charge records: 6 View all charges

Deals & funding

Concord Drugs Limited has 30 deals on record (29 market trades, 1 funding round), with disclosed funding of ₹4.15 Cr; the latest was in July 2025.

Total deals
30
Market trades
29
Funding round
1
Disclosed funding
₹4.15 Cr

Deals on record (5 of 30)

WhenDealAmountParties
Jul 2025Market trade₹38.1 LakhSeller: an individual
Jul 2025Market trade₹85.6 LakhBuyer: an individual
Seller: 2 individuals
Jun 2025Market trade₹19.9 LakhBuyer: an individual
Jan 2024Market trade₹23.2 LakhSeller: an individual
Dec 2023Market trade₹34.7 LakhBuyer: Matalia Stock Broking Private Limited
Seller: Matalia Stock Broking Private Limited

To see the full deal history of Concord Drugs Limited, buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

Credit ratings & regulatory alerts

Concord Drugs Limited was last rated by Crisil on 30 Nov 2019.

Rating agencyRated onRating
Crisil30 Nov 2019

To see the full credit ratings and regulatory alerts of Concord Drugs Limited, buy the company report.

MSME payment delays

No delayed payments to MSME suppliers are on our record for Concord Drugs Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.

Group structure & subsidiaries

Concord Drugs has 1 subsidiary company. This group structure data is as of FY 2023. The table lists each entity with its relationship and holding.

1
Subsidiary companies
Key subsidiaries
Company NameCINShares held
Proton Remedies Private LimitedU24232TG2008PTC061073

To see the full group structure of Concord Drugs Limited, buy the company report.

Employees & EPFO

Concord Drugs Limited has a workforce of 20 employees on its EPFO records as of Mar 29, 2025, across 2 active EPFO establishments.

Employee count
20
Active EPFO establishments
2
Employee growth
-4.76%

GST

Concord Drugs has 3 GST registrations: 1 active and 2 cancelled or inactive.

Total GSTINs
3
Active
1
Cancelled / inactive
2
GSTINStateStatusRegistered on
36AAACC8171D1ZVTelanganaActive01 Jul 2017

To see the full GST registrations and return filing status of Concord Drugs Limited, buy the company report.

Recent activity

Concord Drugs Limited has 26 board changes on record since 1995: 17 appointments and 9 cessations. The latest: Satyam Reddy Gopidi was appointed as Director on 30 Sep 2025.

Charges
A charge with State Bank Of India of Rs. 18.93 Cr registered on 17 Dec 2011 with Charge ID 10394597 was modified on 01 Jul 2026.
Filing
Concord Drugs Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Hyderabad.
Charges
A charge with Others amounted to Rs. 0.40 Cr with Charge ID 101249024 was registered on 25 Feb 2026.
AGM
Concord Drugs Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records.
Appointed
Satyam Reddy Gopidi was appointed as Director.
Appointed
Namratha was appointed as Company Secretary.
Charges
A charge registered on 11 Mar 2022 via Charge ID 100568210 with Others was fully satisfied on 18 Apr 2023.
Ceased
Ankur Bisht ceased to be Company Secretary.
Appointed
Ankur Bisht was appointed as Company Secretary.
Ceased
Chandra Kala Panthamvar ceased to be Additional Director.
Appointed
Sumeela Kasu was appointed as Director.
Charges
A charge with Others amounted to Rs. 5.00 Cr with Charge ID 100568210 was registered on 11 Mar 2022.

30 earlier events are in the company report.

News

Frequently asked questions

Concord Drugs is an active public limited company based in Telangana, India. The company works in api manufacturers, within the pharma industry. It was incorporated on 24 April 1995 (31+ years old) and is registered under CIN L24230TG1995PLC020093. Listed on BSE: 538965.

Concord Drugs reported revenue of ₹78.77 Cr for FY 2025-26 (up 74.1% YoY) based on consolidated financials.

Concord Drugs has 6 current directors:

The latest financial statements of Concord Drugs on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.

The GSTIN of Concord Drugs is 36AAACC8171D1ZV, registered in Telangana. The company has 3 GST registrations in all, of which 1 is active and 2 are cancelled or inactive.

The CIN (Corporate Identification Number) of Concord Drugs is L24230TG1995PLC020093. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Concord Drugs is a listed company as per MCA records. Its shares are listed on BSE (code: 538965).

Concord Drugs has 57 court cases on record: 12 filed by the company and 45 filed against it. 11 are pending. Most are in the district courts.

Concord Drugs was incorporated on 24 April 1995, making it 31+ years old. It is registered with the Registrar of Companies, Hyderabad.

Concord Drugs has 30 deals on record (29 market trades, 1 funding round), with disclosed funding of ₹4.15 Cr; the latest was in July 2025.

The peers of Concord Drugs by revenue are Abhilasha Pharma Private Limited, R L Chemical Industries Private Limited, Maithili Life Sciences Private Limited, Sainor Life Sciences Private Limited, Amara Labs Private Limited and 4 more, all in the Pharma industry (API Manufacturers), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).